IMPROVED FLUOROURACIL-BASED MULTI-AGENT CHEMOTHERAPY FOR TREATMENT OF METASTATIC COLORECTAL CANCER

摘要

This invention is in the area of improved colorectal cancer treatment protocols that provide reduced toxicity compared to currently used regimens, including reduced chemotherapy -induced myelosuppression (CIM), diarrhea, mucositis, and/or stomatitis, while, in some embodiments, also improving anti-cancer efficacy. The improved protocols incorporate a highly selective, transient cyclin dependent kinase (CDK) 4/6 inhibitor into the colorectal cancer treatment protocol, allowing for the expanded use of effective fluorouracil-based multi-agent chemotherapies, for example FOLFOXIRI or FOLFIRINOX, into patient populations previously excluded from these protocols.